Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

Novo Nordisk’s diabetes drug Ozempic has shown promise in reducing alcohol consumption among individuals with alcohol use ...

Novo Nordisk A/S’s Ozempic helped reduce alcohol cravings in a small study, more evidence that the popular injections may ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just<a class="excerpt-read-more" href=" More ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...